Päivi Siltala new CEO of Biohit Oyj

Report this content

Biohit Oyj stock exchange release 29th of July 2021 at 09.00 am local time (EET)

Changes in Management

The Board of Directors of Biohit Oyj has appointed MA Päivi Siltala the CEO of the company starting September 1, 2021. Siltala is joining Biohit from Johnson & Johnson where she has been Sales Director.

Siltala is an experienced biotechnology professional with a large international contact network. She also has a solid track record in managing business development and growth. Siltala has worked in Biohit 2008-2010 and thus knows the company and the technology, which speeds up operative integration.

“Siltala’s experience in biotechnology and personal qualities and skills makes her excellent person to lead and develop Biohit business and operations to materialize company’s commercial potential in the best possible way”, says Eero Lehti, Chairman of the Board of Directors.

Beside Biohit and Johnson & Johnson, Siltala has worked in leading sales and business development positions at Pentax Medical and Cook Medical Endoscopy.


Additional information: 
Chairman of the Board of Directors Eero Lehti, Biohit Oyj
tel. +358 9 773 861



Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com